Rating of The Day: Analysts at FinnCap Kept their “Buy” rating for Abzena (LON:ABZA) with GBX 100.00 PT

November 30, 2016 - By Adrian Mccoy

Abzena (LON:ABZA) Rating

In analysts report issued on 30 November, Abzena (LON:ABZA) stock “Buy” was kept by FinnCap. They currently have a GBX 100.00 target price on the stock. FinnCap’s target price would suggest a potential upside of 194.12% from the company’s last stock close price.

Abzena PLC (LON:ABZA) Ratings Coverage

Out of 2 analysts covering Abzena Plc (LON:ABZA), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. GBX 100 is the highest target while GBX 98 is the lowest. The GBX 99 average target is 200.64% above today’s (GBX 32.93) stock price. Abzena Plc has been the topic of 12 analyst reports since September 14, 2015 according to StockzIntelligence Inc. The firm has “Corporate” rating given on Thursday, January 7 by N+1 Singer. The stock of Abzena PLC (LON:ABZA) has “Corporate” rating given on Tuesday, November 24 by N+1 Singer. FinnCap maintained Abzena PLC (LON:ABZA) on Friday, November 18 with “Buy” rating. The stock of Abzena PLC (LON:ABZA) has “Corporate” rating given on Wednesday, November 30 by N+1 Singer. The firm earned “Buy” rating on Monday, October 12 by N+1 Singer. N+1 Singer maintained it with “Buy” rating and GBX 98 target price in Monday, September 14 report. As per Thursday, November 24, the company rating was maintained by N+1 Singer. The firm has “Buy” rating given on Tuesday, November 29 by FinnCap. The firm has “Corporate” rating by N+1 Singer given on Friday, October 21. The company was maintained on Monday, September 21 by N+1 Singer.

About 102,500 shares traded hands or 1020.46% up from the average. Abzena PLC (LON:ABZA) has declined 34.34% since April 29, 2016 and is downtrending. It has underperformed by 39.57% the S&P500.

Abzena plc is a life sciences company. The company has a market cap of 45.30 million GBP. The Firm provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It currently has negative earnings. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups.

Another recent and important Abzena PLC (LON:ABZA) news was published by Businesswire.com which published an article titled: “Abzena plc: Placing to Raise £20 Million and Acquisition” on November 24, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>